Women's health and oncology out as Teva realigns pipeline
This article was originally published in Scrip
Executive Summary
After a strategic review of its core therapeutic areas, Teva Pharmaceutical is getting rid of 14 pipeline products in order to cut R&D costs in areas it no longer considers key.